• LY2603618: Optimizing Chk1 Inhibitor Workflows for Cancer Re

  2026-07-30

  LY2603618 is a highly selective Chk1 inhibitor that empowers researchers to dissect DNA damage response mechanisms and enhance chemotherapy sensitization in p53-mutant and chemoresistant cancer models. This article translates recent breakthroughs—like PPP2R2A-guided stratification—into actionable protocols, troubleshooting strategies, and advanced applications for precision oncology.

• G418 Sulfate (Geneticin): Applied Selection and Antiviral Wo

  2026-07-30

  G418 Sulfate (Geneticin) from APExBIO is a gold-standard selection antibiotic, uniquely enabling both genetic engineering and antiviral research. This guide delivers hands-on protocols, troubleshooting insights, and practical takeaways from cutting-edge studies to empower robust, reproducible cell-based assays.

• Addressing Lab Assay Challenges with 2'3'-cGAMP (Sodium Salt

  2026-07-29

  This in-depth guide demonstrates how 2'3'-cGAMP (sodium salt) (SKU B8362) from APExBIO addresses key hurdles in cell viability, proliferation, and cytotoxicity assays. Drawing on recent literature and validated protocols, the article equips researchers with data-backed answers for reproducibility, protocol optimization, and product selection in immunology and cancer biology workflows.

• Acetylspiramycin (Spiramycin B): Advancing Translational Res

  2026-07-29

  This thought-leadership article bridges mechanistic insight and strategic guidance for translational researchers confronting antimicrobial resistance. By integrating evidence from biosynthetic studies, clinical surveillance, and advanced resistance protocols, we outline how Acetylspiramycin (Spiramycin B) uniquely enables robust experimental design, immune modulation studies, and next-generation susceptibility testing. The discussion spotlights APExBIO’s product as a solution for resistance research, connects to recent advances in the field, and offers a forward-looking outlook on the evolving landscape of macrolide antibiotics.

• AG-221 (Enasidenib) in AML: Applied Workflows & Troubleshoot

  2026-07-28

  AG-221 (Enasidenib) uniquely enables researchers to model and reverse IDH2 R140Q-driven metabolic rewiring in acute myeloid leukemia, linking oncometabolite suppression to cell differentiation. Explore advanced, reproducible experimental protocols, troubleshooting guidance, and actionable insights inspired by the latest metabolic vulnerability research.

• DeferoxamineB: Optimizing Iron Chelation in Cancer Research

  2026-07-28

  Deferoxamine (DeferoxamineB) is redefining iron modulation, enabling precise control of ferroptosis and cuproptosis in advanced cancer models. This guide details experimental workflows, troubleshooting tips, and innovative protocol enhancements to maximize the impact of this versatile iron chelator.

• Real-World Solutions with Cy5 Tyramide Signal Amplification

  2026-07-27

  This article addresses persistent challenges in fluorescent detection workflows and demonstrates how the Cy5 Tyramide Signal Amplification (TSA) Fluorescence System Kit (SKU K1052) delivers robust, quantitative improvements for immunohistochemistry, immunocytochemistry, and in situ hybridization. Through scenario-driven analysis and protocol insight, biomedical researchers will learn how to achieve reliable data and maximize detection sensitivity using this advanced tyramide signal amplification kit.

• Recombinant Human FGF-19: Mechanistic Insights for Metabolic

  2026-07-27

  Explore the mechanistic role of Recombinant Human FGF-19 in metabolic regulation and its emerging relevance in renal inflammation and pyroptosis research. This article delivers advanced scientific context and protocol guidance for researchers seeking robust, translational insights.

• Pharmacokinetics of CSBTA in MASH: Enzyme and Transporter Dy

  2026-07-26

  This study elucidates how metabolic dysfunction-associated steatohepatitis (MASH) significantly alters the pharmacokinetic and tissue distribution profiles of Corydalis saxicola Bunting total alkaloids (CSBTA) in mice. By integrating enzyme and transporter analyses, the research provides a mechanistic basis for refining dosing regimens in MASLD/MASH therapy.

• Nanocrystal Formulation Boosts Ziprasidone HCl Permeability

  2026-07-25

  This study demonstrates that nanocrystal technology significantly enhances the intestinal permeability of ziprasidone hydrochloride, a second-generation antipsychotic. Using Caco-2 cell models, the research shows a 2.3-fold increase in permeability compared to coarse powder, suggesting a promising strategy to improve oral bioavailability for neuroscience and oncology applications.

• ML216, BLM Helicase Inhibitor: Novel Strategies for Syntheti

  2026-07-24

  Explore ML216, a potent BLM helicase inhibitor, and its transformative role in targeting DNA repair vulnerabilities in cancer. This article delivers a deep dive into mechanistic insights and practical protocols, offering perspectives not found in existing resources.

• p53/PUMA-Dependent Synthetic Lethality via WRN Inhibition in

  2026-07-24

  This study uncovers the molecular mechanism by which Werner (WRN) helicase inhibition induces selective apoptosis in mismatch repair-deficient (MSI) colorectal cancer (CRC) cells. The work identifies a critical dependence on p53 and its effector PUMA for this synthetic lethal effect, providing a mechanistic rationale for targeting WRN in p53-wildtype MSI CRC.

• Genetic Enhancement of A40926 Production in Nonomuraea spp.

  2026-07-23

  This study pioneers molecular strategies to boost A40926, a glycopeptide antibiotic and dalbavancin precursor, in Nonomuraea gerenzanensis. By developing new promoter systems and regulatory gene overexpression, the research demonstrates significant improvements in antibiotic yield, with implications for antibiotic development and resistant pathogen research.

• CCR7–Notch1 Crosstalk Drives Mammary Cancer Stemness

  2026-07-23

  Boyle et al. (2017) reveal that functional interplay between CCR7 and Notch1 signaling axes promotes stem-like properties in mammary cancer cells. This mechanistic insight highlights dual targeting as a potential strategy to inhibit cancer stem cell-driven tumor progression and therapy resistance.

• Cy3 Goat Anti-Rabbit IgG (H+L) Antibody: Precision in Immuno

  2026-07-22

  Unlock high-sensitivity detection of rabbit IgG with the Cy3 Goat Anti-Rabbit IgG (H+L) Antibody. This Cy3-conjugated secondary antibody elevates immunofluorescence and IHC workflows with robust signal amplification and workflow flexibility—empowering reliable results even in demanding research settings.

15964 records 1/1065 page Next 12345 下5页 Last page